Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Insiders have been trading these 5 stocks: (($LLY)), (($MCD)), (($MRVL)), (($DAL)) and (($RTX)). Here is a breakdown of their recent trades and ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly's stock isn't cheap The company's stock trades at a hefty 39 times forward earnings. That's very high for a pharma company and more than twice its main GLP-1 competitor, Novo Nordisk .

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Assessing Eli Lilly's Performance Against Competitors In Pharmaceuticals Industry November 05, 2024 — 10:00 am EST Written by Benzinga Insights for Benzinga -> ...

Eli Lilly (NYSE:LLY) is scheduled to release its earnings report on Thursday, May 1, 2025. For event-driven traders, historical stock performance following earnings announcements may offer ...